James S. Hu, MD
|
Title(s) | Clinical Associate Professor of Medicine (Clinician Educator) |
---|
Phone | +1 323 865 0813 |
---|
vCard | Download vCard |
---|
|
|
Biography American College of Physicians | 2006 | | Fellow | Keck School of Medicine | 2011 | | Oncology Fellowship Teacher of the Year | | 2013 | | Meritorious Service Medal |
Overview James Hu, MD, FACP, is the medical director of the Sarcoma Program of USC, and is considered one of the nation’s experts in the disease. Dr. Hu has more than 20 years of clinical experience in medical oncology and brings this acumen to the bedside. Understanding the rarity of sarcoma cancers, Dr. Hu has the breadth of clinical experience as well as the academic discipline to provide each patient with an individualized treatment program. He has collaborated with other national experts to bring clinical trials to USC. He is a member of the Connective Tissue Oncology Society, and has linked the Sarcoma Program of USC with the international collaborative group: Sarcoma Alliance for Research through Collaboration (SARC), to further direct research into sarcoma.
Dr Hu has authored several review articles on sarcoma, in both national and international peer reviewed journals. As a former military commander of a combat support hospital, Dr. Hu has years of experience in the issues surrounding young adult disease and along with Dr. Siegel, is the co-director of the Adolescent and Young Adult program of USC and Children’s Hospital Los Angeles. This program offers specialized services tailored to adolescent and young adult patients who comprise a significant portion of patients diagnosed with sarcomas. Dr Hu and his medical oncology team pride themselves on patient accessibility and are committed to providing comprehensive oncology care to the patient with sarcoma.
Dr. Hu is a local Angeleno, having grown up in the neighborhood surrounding LAC+USC Medical Center. Dr Hu is proud to be a part of USC and grateful for an opportunity to give back to his community.
ORNG Applications Bibliographic
-
Tseng WW, Pasquali S, Hu JS, Menendez LR, Gronchi A. Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? Chin Clin Oncol. 2019 Mar 06. PMID: 30943728.
-
Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. PMID: 30450405.
-
Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. PMID: 28832978.
-
In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. PMID: 28794805.
-
Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW. Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):39. PMID: 26092408.
-
Gulati M, Hu JS, Desai B, Hwang DH, Grant EG, Duddalwar VA. Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas. J Ultrasound Med. 2015 Aug; 34(8):1489-99. PMID: 26206837.
-
Dorff TB, Hu JS, Quinn DI. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. PMID: 25134324.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|